Huang Shih-Yi, Jeng Chii, Kao Shou-Chuan, Yu Joseth Jy-Hau, Liu Der-Zen
Graduate Institute of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan.
Clin Nutr. 2004 Aug;23(4):615-21. doi: 10.1016/j.clnu.2003.10.010.
BACKGROUND & AIMS: Abnormal haemorrheological property changes in erythrocyte deformability, plasma and blood viscosity, and blood viscoelasticity may play very important roles in the development of microangiopathies in diabetes mellitus (DM). In this study, we demonstrate the improvement in abnormal haemorrheological parameters in DM with ingestion of Ginkgo biloba extract 761 (Egb 761).
Haemorrheological parameters before and 3 months after Egb 761 oral ingestion were determined in 25 type 2 DM patients with retinopathy. These parameters included lipid peroxidation stress of erythrocytes, erythrocyte deformability, plasma and blood viscosity, blood viscoelasticity, and retinal capillary blood flow velocity.
After taking Egb 761 orally for 3 months, the blood viscosity was significantly reduced at different shear rates, by 0.44 +/- 0.10 (gamma = 400), 0.52 +/- 0.09 (gamma = 150) and 2.88 +/- 0.57 (gamma = 5). Viscoelasticity was significantly reduced in diabetic patients by 3.08 +/- 0.78 (0.1 Hz). The level of erythrocyte malondialdehyde (MDA) was reduced by 30%; however, the deformability of erythrocyte was increased by 20%. And lastly, retinal capillary blood flow rate was increased from 3.23 +/- 0.12 to 3.67 +/- 0.24 cm min(-1).
In this preliminary clinical study, 3 months of oral administration of Egb 761 significantly reduced MDA levels of erythrocytes membranes, decreased fibrinogen levels, promoted erythrocytes deformability, and improved blood viscosity and viscoelasticity, which may facilitate blood perfusion. Furthermore, it effectively improved retinal capillary blood flow rate in type 2 diabetic patients with retinopathy.
红细胞变形性、血浆及血液黏度以及血液黏弹性等血液流变学特性的异常变化,可能在糖尿病微血管病变的发生发展中起重要作用。在本研究中,我们证实了摄入银杏叶提取物761(Egb 761)可改善糖尿病患者的异常血液流变学参数。
对25例患有视网膜病变的2型糖尿病患者,测定其口服Egb 761前及口服3个月后的血液流变学参数。这些参数包括红细胞脂质过氧化应激、红细胞变形性、血浆及血液黏度、血液黏弹性以及视网膜毛细血管血流速度。
口服Egb 761 3个月后,不同剪切率下的血液黏度显著降低,在γ = 400时降低0.44±0.10,在γ = 150时降低0.52±0.09,在γ = 5时降低2.88±0.57。糖尿病患者的黏弹性在0.1 Hz时显著降低3.08±0.78。红细胞丙二醛(MDA)水平降低30%;然而,红细胞变形性增加20%。最后,视网膜毛细血管血流速度从3.23±0.12增加至3.67±0.24 cm·min⁻¹。
在这项初步临床研究中,口服Egb 761 3个月可显著降低红细胞膜的MDA水平,降低纤维蛋白原水平,促进红细胞变形性,改善血液黏度和黏弹性,这可能有助于血液灌注。此外,它有效改善了患有视网膜病变的2型糖尿病患者的视网膜毛细血管血流速度。